Patients with severe, asymptomatic aortic stenosis (AS) benefit from early transcatheter aortic valve replacement (TAVR) regardless of baseline biomarker levels, but these benefits are more pronounced in patients with lower levels of biomarkers, a sub-analysis of the EARLY TAVR trial shows.